Literature DB >> 16240913

[Serum creatine kinase activity in dogs and cats with metabolic diseases].

S Neumann1.   

Abstract

Elevated Creatine kinase-activitiy (CK) indicates disturbances of the muscle cell integrity. In addition to primary muscle disease, like trauma, inflammation or dystrophy, diseases of other organs can lead to secondary muscle involvement, which will be indicated by increased serum activities of the CK. The mechanisms of muscle cell disturbance are still unknown. An elevated protein catabolism in the muscle cell is suspected. In the present study we investigated, if dogs and cats with metabolic diseases have increased CK-activity in the serum. From 34 dogs and cats in a group with different metabolic diseases without metabolic acidosis 19% of the dogs and 50% of the cats had increased CK-activity in the serum. From 33 dogs and cats with different metabolic diseases connected with metabolic acidosis 86% of the dogs and 95% of the cats had simultaneously increased CK-activity in the serum. In comparison to healthy dogs and cats animals with metabolic diseases have significant and in cases of metabolic di-seases with metabolic acidosis cats have high significant elevation (dogs significant) of CK-activity in the serum. There was no significant correlation between the groups of patients. In conclusion we think that our results show that metabolic diseases often induce secondary myopathy, measured by CK-activity in the serum, but metabolic acidosis has no direct influence on elevated CK activity in dogs and cats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16240913

Source DB:  PubMed          Journal:  Dtsch Tierarztl Wochenschr        ISSN: 0341-6593


  1 in total

1.  Electrophoretic fractionation of creatine kinase isoenzymes and macroenzymes in clinically healthy dogs and cats and preliminary evaluation in central neurologic disease.

Authors:  Saverio Paltrinieri; Stefania Cazzaniga; Nazarè Pinto da Cunha; Alessia Giordano
Journal:  Vet Clin Pathol       Date:  2010-08-02       Impact factor: 1.180

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.